Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo.
Animals
Antibodies, Monoclonal, Humanized
/ immunology
Bone Marrow
/ immunology
CD3 Complex
/ antagonists & inhibitors
CD4 Antigens
/ administration & dosage
Gene Expression Regulation
/ immunology
HIV Envelope Protein gp41
/ antagonists & inhibitors
HIV Infections
/ immunology
HIV-1
/ immunology
Humans
Immunotherapy, Adoptive
Liver
/ immunology
Mice
Peptide Fragments
/ antagonists & inhibitors
Protein Domains
/ immunology
Receptors, CXCR4
/ antagonists & inhibitors
Receptors, Chimeric Antigen
/ administration & dosage
T-Lymphocytes
/ immunology
Thymus Gland
/ immunology
Tumor Necrosis Factor Receptor Superfamily, Member 9
/ antagonists & inhibitors
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
27
01
2020
accepted:
28
07
2020
pubmed:
2
9
2020
medline:
9
1
2021
entrez:
2
9
2020
Statut:
ppublish
Résumé
An effective strategy to cure HIV will likely require a potent and sustained antiviral T cell response. Here we explored the utility of chimeric antigen receptor (CAR) T cells, expressing the CD4 ectodomain to confer specificity for the HIV envelope, to mitigate HIV-induced pathogenesis in bone marrow, liver, thymus (BLT) humanized mice. CAR T cells expressing the 4-1BB/CD3-ζ endodomain were insufficient to prevent viral rebound and CD4
Identifiants
pubmed: 32868878
doi: 10.1038/s41591-020-1039-5
pii: 10.1038/s41591-020-1039-5
pmc: PMC9422086
mid: NIHMS1827405
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
CD3 Complex
0
CD3 antigen, zeta chain
0
CD4 Antigens
0
CXCR4 protein, mouse
0
HIV Envelope Protein gp41
0
Peptide Fragments
0
Receptors, CXCR4
0
Receptors, Chimeric Antigen
0
Tumor Necrosis Factor Receptor Superfamily, Member 9
0
peptide C34
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1776-1787Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI126620
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007632
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI164570
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI117950
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI045008
Pays : United States
Organisme : NHLBI NIH HHS
ID : U19 HL129903
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI149680
Pays : United States
Organisme : NIAID NIH HHS
ID : F32 AI136750
Pays : United States
Références
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
pubmed: 29972754
pmcid: 7433347
doi: 10.1056/NEJMra1706169
Walker, B. & McMichael, A. The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2, 1–19 (2012).
doi: 10.1101/cshperspect.a007054
Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024–10028 (1989).
pubmed: 2513569
doi: 10.1073/pnas.86.24.10024
pmcid: 298636
van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Disco. 14, 499–509 (2015).
doi: 10.1038/nrd4597
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
pubmed: 25317870
pmcid: 4267531
Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
pubmed: 26333935
pmcid: 5909068
doi: 10.1126/scitranslmed.aac5415
Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426–5435 (2007).
pubmed: 17855649
doi: 10.1158/1078-0432.CCR-07-0674
Song, D. G. et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617–4627 (2011).
pubmed: 21546571
pmcid: 4140173
doi: 10.1158/0008-5472.CAN-11-0422
Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360–3365 (2009).
pubmed: 19211796
doi: 10.1073/pnas.0813101106
pmcid: 2651342
Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009).
pubmed: 19384291
pmcid: 2805264
doi: 10.1038/mt.2009.83
Cheng, Z. et al. In vivo expansion and antitumor activity of coinfused CD28- and 4-1BB-engineered CAR-T cells in patients with B cell leukemia. Mol. Ther. 26, 976–985 (2018).
pubmed: 29503204
pmcid: 6079368
doi: 10.1016/j.ymthe.2018.01.022
Quintarelli, C. et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 7, e1433518 (2018).
pubmed: 29872565
pmcid: 5980417
doi: 10.1080/2162402X.2018.1433518
Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380–390 (2016).
pubmed: 26885860
doi: 10.1016/j.immuni.2016.01.021
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
pubmed: 29226797
pmcid: 5882485
Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018).
pubmed: 29385376
pmcid: 6637939
doi: 10.1056/NEJMoa1709919
Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).
pubmed: 30131370
pmcid: 6186424
doi: 10.1126/scisignal.aat6753
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
pubmed: 30501490
doi: 10.1056/NEJMoa1804980
Abate-Daga, D. & Davila, M. L. CAR models: next-generation CAR modifications for enhanced T-cell function. Mol. Ther. Oncolytics 3, 16014 (2016).
pubmed: 27231717
pmcid: 4871190
doi: 10.1038/mto.2016.14
Weinkove, R., George, P., Dasyam, N. & McLellan, A. D. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin. Transl. Immunol. 8, e1049 (2019).
doi: 10.1002/cti2.1049
Deeks, S. G. et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5, 788–797 (2002).
pubmed: 12027564
doi: 10.1006/mthe.2002.0611
Colovos, C., Villena-Vargas, J. & Adusumilli, P. S. Safety and stability of retrovirally transduced chimeric antigen receptor T cells. Immunotherapy 4, 899–902 (2012).
pubmed: 23046233
doi: 10.2217/imt.12.91
Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra153 (2012).
doi: 10.1126/scitranslmed.3003761
Kim, G. B., Hege, K. & Riley, J. L. CAR talk: how cancer-specific CAR T cells can instruct how to build CAR T cells to cure HIV. Front. Immunol. 10, 2310 (2019).
pubmed: 31611880
pmcid: 6776630
doi: 10.3389/fimmu.2019.02310
Ali, A. et al. HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J. Virol. 90, 6999–7006 (2016).
pubmed: 27226366
pmcid: 4944295
doi: 10.1128/JVI.00805-16
Hale, M. et al. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol. Ther. 25, 570–579 (2017).
pubmed: 28143740
pmcid: 5363191
doi: 10.1016/j.ymthe.2016.12.023
Leibman, R. S. et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. 13, e1006613 (2017).
pubmed: 29023549
pmcid: 5638568
doi: 10.1371/journal.ppat.1006613
Zhen, A. et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. PLoS Pathog. 13, e1006753 (2017).
pubmed: 29284044
pmcid: 5746250
doi: 10.1371/journal.ppat.1006753
Anthony-Gonda, K. et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci. Transl. Med. 11, eaav5685 (2019).
pubmed: 31391322
pmcid: 7136029
doi: 10.1126/scitranslmed.aav5685
Herzig, E. et al. Attacking latent HIV with convertibleCAR-T cells, a highly adaptable killing platform. Cell 179, e810 (2019).
doi: 10.1016/j.cell.2019.10.002
Sun, Z. et al. Intrarectal transmission, systemic infection, and CD4
pubmed: 17389241
pmcid: 2118553
doi: 10.1084/jem.20062411
Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, e16 (2008).
pubmed: 18198941
pmcid: 2194746
doi: 10.1371/journal.pmed.0050016
Brainard, D. M. et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J. Virol. 83, 7305–7321 (2009).
pubmed: 19420076
pmcid: 2704767
doi: 10.1128/JVI.02207-08
Zhen, A. et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J. Clin. Invest. 127, 260–268 (2017).
pubmed: 27941243
doi: 10.1172/JCI89488
Boritz, E. A. et al. Multiple origins of virus persistence during natural control of HIV infection. Cell 166, 1004–1015 (2016).
pubmed: 27453467
pmcid: 4983216
doi: 10.1016/j.cell.2016.06.039
Estes, J. D. et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 23, 1271–1276 (2017).
pubmed: 28967921
pmcid: 5831193
doi: 10.1038/nm.4411
Ventura, J. D. et al. Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. PLoS Pathog. 15, e1008161 (2019).
pubmed: 31805155
pmcid: 6917343
doi: 10.1371/journal.ppat.1008161
Alfei, F. et al. TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571, 265–269 (2019).
doi: 10.1038/s41586-019-1326-9
pubmed: 31207605
Khan, O. et al. TOX transcriptionally and epigenetically programs CD8
pubmed: 31207603
pmcid: 6713202
doi: 10.1038/s41586-019-1325-x
Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270–274 (2019).
doi: 10.1038/s41586-019-1324-y
pubmed: 31207604
pmcid: 7698992
Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8
doi: 10.1073/pnas.1905675116
pubmed: 31152140
pmcid: 6589758
Yao, C. et al. Single-cell RNA-seq reveals TOX as a key regulator of CD8
pubmed: 31209400
pmcid: 6588409
doi: 10.1038/s41590-019-0403-4
Appay, V. et al. Memory CD8
pubmed: 11927944
doi: 10.1038/nm0402-379
Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8
pubmed: 25032686
pmcid: 4102564
doi: 10.1371/journal.ppat.1004251
Leslie, G. J. et al. Potent and broad inhibition of HIV-1 by a peptide from the gp41 heptad repeat-2 domain conjugated to the CXCR4 amino terminus. PLoS Pathog. 12, e1005983 (2016).
pubmed: 27855210
pmcid: 5113989
doi: 10.1371/journal.ppat.1005983
Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415–428 (2015).
pubmed: 26461090
pmcid: 5003056
doi: 10.1016/j.ccell.2015.09.004
Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, e96976 (2018).
pmcid: 5821198
doi: 10.1172/jci.insight.96976
Pule, M. A. et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12, 933–941 (2005).
pubmed: 15979412
doi: 10.1016/j.ymthe.2005.04.016
Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M. & Abken, H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4
pubmed: 22754764
pmcid: 3382912
doi: 10.4161/onci.19855
Moir, S., Chun, T. W. & Fauci, A. S. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223–248 (2011).
pubmed: 21034222
doi: 10.1146/annurev-pathol-011110-130254
Perez, E. E. et al. Establishment of HIV-1 resistance in CD4
pubmed: 18587387
pmcid: 3422503
doi: 10.1038/nbt1410
Holt, N. et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839–847 (2010).
pubmed: 20601939
pmcid: 3080757
doi: 10.1038/nbt.1663
Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014).
pubmed: 24597865
pmcid: 4084652
doi: 10.1056/NEJMoa1300662
Peterson, C. W. et al. Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: implications for HIV gene therapy. PLoS Pathog. 14, e1006956 (2018).
pubmed: 29672640
pmcid: 5908070
doi: 10.1371/journal.ppat.1006956
Claiborne, D. T. et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4
pubmed: 25730868
doi: 10.1073/pnas.1421607112
pmcid: 4378387
Wright, J. K. et al. Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J. Virol. 85, 3996–4006 (2011).
pubmed: 21289112
pmcid: 3126116
doi: 10.1128/JVI.02520-10
Prince, J. L. et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog. 8, e1003041 (2012).
pubmed: 23209412
pmcid: 3510241
doi: 10.1371/journal.ppat.1003041
Deymier, M. J. et al. Heterosexual transmission of subtype C HIV-1 selects consensus-like variants without increased replicative capacity or interferon-ɑ resistance. PLoS Pathog. 11, e1005154 (2015).
pubmed: 26378795
pmcid: 4574710
doi: 10.1371/journal.ppat.1005154
Seung, E. & Tager, A. M. Humoral immunity in humanized mice: a work in progress. J. Infect. Dis. 208(Suppl 2), S155–S159 (2013).
pubmed: 24151323
pmcid: 3807975
doi: 10.1093/infdis/jit448
Martinez-Torres, F., Nochi, T., Wahl, A., Garcia, J. V. & Denton, P. W. Hypogammaglobulinemia in BLT humanized mice—an animal model of primary antibody deficiency. PLoS ONE 9, e108663 (2014).
pubmed: 25271886
pmcid: 4182704
doi: 10.1371/journal.pone.0108663
Karpel, M. E., Boutwell, C. L. & Allen, T. M. BLT humanized mice as a small animal model of HIV infection. Curr. Opin. Virol. 13, 75–80 (2015).
pubmed: 26083316
pmcid: 4550544
doi: 10.1016/j.coviro.2015.05.002
Dudek, T. E. et al. Rapid evolution of HIV-1 to functional CD8
doi: 10.1126/scitranslmed.3003984
Claiborne, D. T. et al. Immunization of BLT humanized mice redirects T cell responses to Gag and reduces acute HIV-1 viremia. J. Virol. 93, e00814–e00819 (2019).
pubmed: 31375576
pmcid: 6798105
doi: 10.1128/JVI.00814-19
Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).
pubmed: 28251988
pmcid: 5337964
doi: 10.1038/ncomms14630
Boutwell, C. L., Rowley, C. F. & Essex, M. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J. Virol. 83, 2460–2468 (2009).
pubmed: 19109381
doi: 10.1128/JVI.01970-08
Johnson, D. et al. Expression and structure of the human NGF receptor. Cell 47, 545–554 (1986).
pubmed: 3022937
doi: 10.1016/0092-8674(86)90619-7
Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263 (2011).
pubmed: 21653320
pmcid: 3152493
doi: 10.1182/blood-2011-02-337360
Brelot, A., Heveker, N., Montes, M. & Alizon, M. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J. Biol. Chem. 275, 23736–23744 (2000).
pubmed: 10825158
doi: 10.1074/jbc.M000776200
Richardson, M. W. et al. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5ɑ. J. Virol. 82, 11117–11128 (2008).
pubmed: 18768965
pmcid: 2573261
doi: 10.1128/JVI.01046-08
Clayton, K. L. et al. Resistance of HIV-infected macrophages to CD8
pubmed: 29670239
pmcid: 6025741
doi: 10.1038/s41590-018-0085-3
Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604–8610 (2011).
pubmed: 22035192
pmcid: 3216358
doi: 10.1021/ac202028g